This was a retrospective study that assessed achievement of lipid-lowering treatment targets in the setting of a University Hospital Lipid Clinic. Low-density lipoprotein cholesterol (LDL-C) goal attainment according to National Cholesterol Education Program-Adult Treatment Panel III (NCEP ATP III) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines was recorded in 1000 consecutive adult patients followed for ≥3 years (mean 8 years). The LDL-C targets according to the NCEP ATP III were attained by 66% and 86% of patients with “very high” (n = 477) and “high” (n = 408) cardiovascular risk, respectively. Fewer patients were within LDL-C goals according to the ESC/EAS guidelines: 25% and 42%. Overall, 92% of the patients were on statins: 67% were on statin monotherapy, while 33% were on combinations with ezetimibe (25%), ω-3 fatty acids (5%), fibrates (4%), or colesevelam (2%). Even in a specialist lipid clinic, a large proportion of patients are not at goal according to the recent ESC/EAS guidelines.
PerkJDe BackerGGohlkeH. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–1701.
2.
CatapanoALReinerZDe BackerG. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis. 2011;217(1):3–46.
3.
WongNDChuangJWongKPhamANeffDMarrettE. Residual dyslipidemia among united states adults treated with lipid modifying therapy (data from national health and nutrition examination survey 2009-2010). Am J Cardiol. 2013;112(3):373–379.
4.
KotsevaKWoodDDe BackerG. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010;17(5):530–540.
5.
KotsevaKWoodDDe BackerGDe BacquerDPyoralaKKeilU. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–940.
6.
KotsevaKWoodDDe BackerGDe BacquerDPyoralaKKeilU. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121–137.
ElisafMSNikasN. Centralized pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs–the CEPHEUS-greece survey. Angiology. 2010;61(5):465–474.
9.
LiberopoulosEVlasserouFMitrogianniZPapageorgantasIElisafM. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology. 2012;63(3):184–193.
10.
AthyrosVGLiberopoulosENMikhailidisDP. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology. 2007;58(6):689–697.
11.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–3421.
12.
ElisafMPitsavosCLiberopoulosEAthyrosV. Guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia. Hellenic J Atherosclerosis. 2011;2(3):163–168.
13.
MarksDThorogoodMNeilHAHumphriesSE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14.
14.
ChinCWGaoFLeTTanR. Lipid goal attainment and prescription behavior in Asian patients with acute coronary syndromes: experience from a tertiary hospital. Clin Med Insights Cardiol. 2013;7:51–57.
15.
PirroMDel GiornoRLupattelliG. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic. Eur J Intern Med. 2011;22(4):412–417.
16.
GhandehariHKamal-BahlSWongND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the national health and nutrition examination survey 2003-2004. Am Heart J. 2008;156(1):112–119.
17.
MalikSLopezVChenRWuWWongND. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77(1):126–133.
18.
JacobsMJKleisliTPioJR. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70(3):263–269.
19.
NagSSDanielGWBullanoMF. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007;13(8):652–663.
20.
Alsheikh-AliAALinJLAbourjailyPAhearnDKuvinJTKarasRH. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007;100(10):1499–1501.
21.
JonesPHNairRThakkerKM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):e001800.
22.
YuBLZhaoSPPengDQHuoYHuL. A comparison of non-HDL and LDL cholesterol goal attainment in the CHILLAS trial. Int J Cardiol. 2013;168(4):4340–4342.
23.
SantosRDWatersDDTarasenkoL. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the lipid treatment assessment project 2. Atherosclerosis. 2012;224(1):150–153.
24.
OlssonAGLindahlCHolmeI. LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. Eur J Cardiovasc Prev Rehabil. 2011;18(2):262–269.
25.
MelloniCShahBROuFS. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the medications applied aNd SusTAINed over time (MAINTAIN) registry. Am Heart J. 2010;160(6):1121–1129.
26.
FerrieresJAmberVCrisanOChazelleFJungerCWoodD. Total lipid management and cardiovascular disease in the dyslipidemia international study. Cardiology. 2013;125(3):154–163.
27.
SachdevaACannonCPDeedwaniaPC. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in get with the guidelines. Am Heart J. 2009;157(1):111–117.
28.
SchaeferJRGittAKSonntagF. Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA registry. Vasc Health Risk Manag. 2013;9:71–80.
29.
StadlerSLBhardwajaBOlsonKLPowersJDLaneseD. An assessment of cholesterol goal attainment in patients with chronic kidney disease. J Clin Lipidol. 2010;4(4):298–304.
30.
KumarAFonarowGCEagleKA. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH registry. Crit Pathw Cardiol. 2009;8(3):104–111.
31.
Penning-van BeestFJTermorshuizenFGoettschWGKlungelOHKasteleinJJHeringsRM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28(2):154–159.
32.
AthyrosVGMikhailidisDPLiberopoulosEN. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek atorvastatin and coronary heart disease evaluation (GREACE) study. Nephrol Dial Transplant. 2007;22(1):118–127.
33.
AthyrosVGTziomalosKGossiosTD. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376(9756):1916–1922.
34.
AthyrosVGMikhailidisDPPapageorgiouAA. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728–734.
35.
BaesslerAFischerMHufV. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol. 2005;101(2):293–298.
36.
LiberopoulosENFlorentinMMikhailidisDPElisafMS, Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf. 2008;7(6):717–725.
37.
BarkasFLiberopoulosEElisafM. Impact of compliance with antihypertensive and lipid-lowering treatment on cardiocascular risk – Benefits of fixed-dose combinations. Hellenic J Atherosclerosis. 2013;4(1):31–39.
38.
AthyrosVGElisafMSAlexandridesT. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology. 2012;63(5):358–366.
39.
SagerHBLinsel-NitschkePMayerB. Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients. Eur Heart J. 2010;31(10):1266–1273.
40.
BuykenAEvon EckardsteinASchulteHCullenPAssmannG. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil. 2007;14(2):230–236.
41.
BulugahapitiyaUSiyambalapitiyaSSitholeJIdrisI. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142–148.
42.
TonelliMMuntnerPLloydA. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012;380(9844):807–814.
43.
BestehornKJannowitzCKarmannBPittrowDKirchW. Characteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in disease management program versus those in routine care: LUTZ registry. BMC Public Health. 2009;9:280.
44.
LawMRWaldNJRudnickaAR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.
45.
LeuschenJMortensenEMFreiCRMansiEAPandayVMansiI. Association of statin use with cataracts: a propensity score–matched analysis. JAMA Ophthalmology. 2013;131(11):1427–1434.
46.
FaergemanOHolmeIFayyadR. Plasma triglycerides and cardiovascular events in the Treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104(4):459–463.
47.
MigdalisIEfthimiadisAPappasSAlexopoulosDVlasserouFMikhailidisDP. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin. 2009;25(10):2571–2576.
48.
StoneNJRobinsonJLichtensteinAH. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129
(25 Suppl 2): S1–S45.
49.
MikhailidisDPAthyrosVG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol. 2014;11(2):72–74.
